Reports / Nephrology Reports / RealWorld Dynamix: Chronic Kidney Disease US
RealWorld Dynamix: Chronic Kidney Disease US
Chronic kidney disease (CKD) affects millions of Americans, with many patients unaware they have the disease. CKD is a progressive disease that ultimately leads to the need for renal replacement therapy via dialysis or transplantation. This report analyzes the population of CKD patients that are under the care of a nephrologist and who have reached Stage 3 (eGFR<60). In addition to a host of clinical and non-clinical demographics, the report quantifies treatment rates for renal medications, distribution of key laboratory values used to assess CKD patients, co-morbid conditions, hospitalizations and number/frequency of office visits.
RealWorld Dynamix™: Chronic Kidney Disease is based on a deep, robust patient chart analysis of +/- 1,000 patients with CKD (eGFR<60) under the care of a nephrologist. Each nephrologist (n=+/-200) completes an in-depth medical history of the most recent 3-7 patients who met the study inclusion criteria. An excellent augmentation to claims data, this study also captures the clinician’s perspective on the why behind treatment decisions. In addition to patient demographics and treatment history, patient origination and status at referral, clinical assessments, diagnostic tests and laboratory values are included to provide insight into the real world treatment patterns in CKD patients.
Learn more about RealWorld Dynamix™ reports here.
- What are the treatment patterns for renal anemia by CKD stage? What percent of patients are treated with ESAs, IV iron and oral iron? What is the average ESA and IV iron dose by stage of CKD? Is ferric citrate currently being used as a treatment for IDA?
- What symptoms are most common in CKD patients? By most recent Hb level, what percent of patients report fatigue?
- What percent of patients by stage are treated with phosphate binders, active vitamin D and nutritional vitamin D? How is Rayaldee being incorporated into current practice patterns? Has the use of non-calcium binders changed considering recent KDIGO guideline updates? Which off these therapies, phosphate binders or active vitamin D, is typically initiated first? Is Sensipar used at all in this population?
- From what specialties are CKD patients most commonly referred and what is their presentation at referral including labs and other assessments? How often are patients seen by the nephrologist (by stage) and which other physicians are involved in the co-management of these patients?
- What is the opportunity for Veltassa in these patients? What percent of patients have a potassium level >5.5 and, among those, what percent are treated with either SPS or Veltassa? Why are patients who present with hyperkalemia not being treated with these agents?
- How do certain co-morbid conditions such as Type 2 diabetes, influence the treatment patterns? What is the Hba1c distribution across the population, what percent are treated with insulin, SGLT2s? How have nephrologists attitudes about SGLT2s and the treatment of DKD changed in the past year?
ACE inhibitors, allopurinol, Aranesp, Auryxia, ARBs, cholecalciferol, calcitriol, calcium-based binders, Colchrys, ergocalciferol, Feraheme, Ferrlecit, Fosrenol, Hectorol, INFeD, Injectafer, oral iron, Procrit, Rayaldee, Renvela, SGLT2s, spironolactone/eplerenone, SPS, tacrolimus, Uloric, various biologics (rituximab), Velphoro, Veltassa, Venofer, Zemplar, Zurampic
In the CKD-MBD Market, OPKO’s Rayaldee Continues to Struggle While Keryx’s Auryxia Gains Momentum, According to Latest Quarterly Update from Spherix Global Insights – November 14, 2017
New Study of More Than 1,000 Dialysis Patients Reveals Significant Opportunity for Improvement of Hyperphosphatemia and Highlights the Potential for Amgen’s Parsabiv – August 3, 2017